# Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)

> **NCT01318200** · PHASE3 · WITHDRAWN · sponsor: **Accuray Incorporated**

## Conditions studied

- Recurrent Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** Transarterial Chemoembolization
- **RADIATION:** CyberKnife SBRT

## Key facts

- **NCT ID:** NCT01318200
- **Lead sponsor:** Accuray Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-02
- **Primary completion:** 2014-02
- **Final completion:** 2016-02
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01318200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01318200, "Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01318200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*